Abstract |
|
Authors | Ohad Benjamini, Preetesh Jain, Long Trinh, Wei Qiao, Sara S Strom, Susan Lerner, Xuemei Wang, Jan Burger, Alessandra Ferrajoli, Hagop Kantarjian, Susan O'Brien, William Wierda, Zeev Estrov, Michael Keating |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 56
Issue 6
Pg. 1643-50
(Jun 2015)
ISSN: 1029-2403 [Electronic] United States |
PMID | 25308294
(Publication Type: Journal Article)
|
Chemical References |
- Rituximab
- Cyclophosphamide
- Vidarabine
- fludarabine
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Cell Transformation, Neoplastic
(chemically induced)
- Cyclophosphamide
(administration & dosage)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Leukemia, Myeloid, Acute
(chemically induced, epidemiology)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(chemically induced, epidemiology)
- Neoplasms, Second Primary
(chemically induced, epidemiology)
- Retrospective Studies
- Risk Factors
- Rituximab
(administration & dosage)
- Survival Rate
- Vidarabine
(administration & dosage, analogs & derivatives)
|